CKD-388 / Chong Kun Dang - LARVOL DELTA

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388(2) in Healthy Subjects (clinicaltrials.gov) - P1 | N=65 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Completed

Trial completion • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388(2) in Healthy Subjects (clinicaltrials.gov) - P1; N=60; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical

Clinical • New P1 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Chong Kun Dang receives approval for three clinical trials at the same time, including glaucoma, hepatitis B, and psoriasis [Google translation] (Health Korea News) - "Chong Kun Dang was approved for clinical trials on three of its drugs at the same time...'CKD-388' is effective in treating chronic hepatitis B in adults. This clinical trial is to evaluate the safety and pharmacokinetics of 'CKD-388' in 60 healthy adult subjects. The implementing organizations were known as Bioinfra and H+ Yangji Hospital. "

New trial • Hepatitis B • Infectious Disease

Chong Kun Dang develops CKD-388, a drug that responds to 'Vemlidi' [Google translation] (CEO Score Daily) - "Chong Kun Dang is speeding up the development of a drug to respond to multinational pharmaceutical company Gilead Sciences' hepatitis B treatment Vemlidi (ingredient name: tenofovir alafenamide hemifumarate)...the reference drug for CKD-388, which Chong Kun Dang is conducting a phase 1 clinical trial, is 'Vemlidi Tablet'...the trial is expected to start in March of this year and end in February next year...The expiration date of the target patent (patent number 10-1612642-0000) for which pharmaceutical companies have requested a patent trial is August 15, 2032."

New P1 trial • Patent • Hepatitis B • Infectious Disease

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388 in Healthy Subjects (clinicaltrials.gov) - P1; N=56; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical

Clinical • New P1 trial • Hepatitis B • Hepatology • Infectious Disease